Cormorant Asset Management as of March 31, 2016
Portfolio Holdings for Cormorant Asset Management
Cormorant Asset Management holds 84 positions in its portfolio as reported in the March 2016 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Alder Biopharmaceuticals | 5.5 | $37M | 1.5M | 24.49 | |
Heron Therapeutics (HRTX) | 5.0 | $33M | 1.8M | 18.99 | |
Sage Therapeutics (SAGE) | 4.6 | $30M | 945k | 32.06 | |
Omeros Corporation (OMER) | 4.5 | $30M | 2.0M | 15.34 | |
Nektar Therapeutics (NKTR) | 4.1 | $28M | 2.0M | 13.75 | |
Nevro (NVRO) | 4.1 | $27M | 485k | 56.26 | |
Alkermes (ALKS) | 3.6 | $24M | 700k | 34.19 | |
Neurocrine Biosciences (NBIX) | 3.6 | $24M | 604k | 39.55 | |
Eagle Pharmaceuticals (EGRX) | 3.0 | $20M | 500k | 40.50 | |
Dynavax Technologies (DVAX) | 2.8 | $19M | 975k | 19.24 | |
Proteostasis Therapeutics In | 2.5 | $17M | 1.7M | 9.64 | |
Alnylam Pharmaceuticals (ALNY) | 2.3 | $15M | 245k | 62.77 | |
Portola Pharmaceuticals | 2.1 | $14M | 700k | 20.40 | |
Quotient | 2.0 | $13M | 1.5M | 8.80 | |
Macrogenics (MGNX) | 2.0 | $13M | 700k | 18.75 | |
Cellectis S A (CLLS) | 1.9 | $13M | 469k | 27.50 | |
Tesaro | 1.9 | $13M | 291k | 44.03 | |
China Biologic Products | 1.9 | $13M | 112k | 114.48 | |
Aclaris Therapeutics (ACRS) | 1.9 | $12M | 648k | 18.95 | |
Coherus Biosciences (CHRS) | 1.8 | $12M | 569k | 21.23 | |
Ardelyx (ARDX) | 1.7 | $12M | 1.5M | 7.77 | |
Vitae Pharmaceuticals | 1.7 | $12M | 1.7M | 6.63 | |
Sorrento Therapeutics (SRNE) | 1.7 | $11M | 2.1M | 5.38 | |
Minerva Neurosciences | 1.6 | $11M | 1.8M | 6.14 | |
Mirati Therapeutics | 1.6 | $11M | 495k | 21.40 | |
Dex (DXCM) | 1.6 | $10M | 153k | 67.91 | |
Celgene Corporation | 1.5 | $10M | 100k | 100.09 | |
Rockwell Medical Technologies | 1.2 | $8.3M | 1.1M | 7.51 | |
Novavax | 1.2 | $8.3M | 1.6M | 5.16 | |
Collegium Pharmaceutical Inc Common Stock Usd (COLL) | 1.2 | $8.2M | 450k | 18.15 | |
Myokardia | 1.2 | $8.1M | 753k | 10.71 | |
Advaxis | 1.1 | $7.2M | 800k | 9.03 | |
Ultragenyx Pharmaceutical (RARE) | 1.0 | $6.9M | 110k | 63.31 | |
Celator Pharmaceuticals | 1.0 | $6.8M | 620k | 11.03 | |
Lipocine | 1.0 | $6.8M | 667k | 10.15 | |
Seres Therapeutics (MCRB) | 1.0 | $6.6M | 250k | 26.56 | |
Agenus | 1.0 | $6.5M | 1.6M | 4.16 | |
Pfenex | 0.9 | $6.1M | 625k | 9.83 | |
Forward Pharma A/s | 0.9 | $5.7M | 335k | 17.00 | |
Wave Life Sciences (WVE) | 0.8 | $5.4M | 392k | 13.88 | |
Acceleron Pharma | 0.8 | $5.3M | 200k | 26.39 | |
Cytomx Therapeutics (CTMX) | 0.7 | $4.8M | 371k | 12.90 | |
Recro Pharma | 0.7 | $4.7M | 780k | 5.97 | |
Zynerba Pharmaceuticals | 0.7 | $4.5M | 475k | 9.45 | |
Achillion Pharmaceuticals | 0.6 | $3.9M | 500k | 7.72 | |
Dermira | 0.5 | $3.5M | 170k | 20.68 | |
Agile Therapeutics | 0.5 | $3.5M | 557k | 6.21 | |
Celyad Sa | 0.5 | $3.3M | 75k | 44.16 | |
Intec Pharma | 0.5 | $3.3M | 800k | 4.12 | |
Epizyme | 0.5 | $3.2M | 266k | 12.12 | |
Kite Pharma | 0.5 | $3.2M | 69k | 45.92 | |
Aptose Biosciences | 0.5 | $3.2M | 1.1M | 2.94 | |
BioCryst Pharmaceuticals (BCRX) | 0.5 | $3.1M | 1.1M | 2.83 | |
Contrafect | 0.4 | $2.8M | 834k | 3.40 | |
Atara Biotherapeutics | 0.4 | $2.9M | 150k | 19.03 | |
Syndax Pharmaceuticals (SNDX) | 0.4 | $2.9M | 214k | 13.32 | |
Bellicum Pharma | 0.4 | $2.8M | 300k | 9.35 | |
Lion Biotechnologies | 0.4 | $2.5M | 500k | 5.08 | |
Immune Design | 0.4 | $2.5M | 189k | 13.00 | |
Ovascience | 0.4 | $2.4M | 252k | 9.49 | |
Epirus Biopharmaceuticals In | 0.4 | $2.4M | 897k | 2.69 | |
Curis | 0.3 | $1.9M | 1.2M | 1.61 | |
Regenxbio Inc equity us cm (RGNX) | 0.3 | $1.7M | 157k | 10.80 | |
Glycomimetics (GLYC) | 0.2 | $1.7M | 284k | 5.96 | |
Aquinox Pharmaceuticals | 0.2 | $1.3M | 150k | 8.82 | |
Biotie Therapies Corp. ads | 0.2 | $1.3M | 50k | 26.40 | |
Amicus Therapeutics (FOLD) | 0.2 | $1.3M | 150k | 8.45 | |
Ascendis Pharma A S (ASND) | 0.2 | $1.1M | 62k | 18.55 | |
Tetralogic Pharmaceuticals c note 8.000% 6/1 | 0.2 | $1.2M | 5.0M | 0.23 | |
AVEO Pharmaceuticals | 0.1 | $1.0M | 1.1M | 0.92 | |
Genvec | 0.1 | $953k | 1.2M | 0.81 | |
Provectus Biopharmaceuticals I (PVCT) | 0.1 | $836k | 2.2M | 0.38 | |
Veracyte (VCYT) | 0.1 | $745k | 138k | 5.40 | |
Nanostring Technologies (NSTGQ) | 0.1 | $609k | 40k | 15.22 | |
Htg Molecular Diagnostics | 0.1 | $577k | 201k | 2.87 | |
Neos Therapeutics | 0.1 | $540k | 50k | 10.80 | |
Threshold Pharmaceuticals | 0.1 | $460k | 1.0M | 0.46 | |
Provectus Biopharmaceuticals *w exp 06/24/202 | 0.1 | $440k | 2.2M | 0.20 | |
Pronai Therapeutics | 0.1 | $358k | 53k | 6.74 | |
Applied Genetic Technol Corp C | 0.0 | $239k | 17k | 13.97 | |
Regulus Therapeutics | 0.0 | $212k | 31k | 6.92 | |
Adaptimmune Therapeutics (ADAP) | 0.0 | $203k | 25k | 8.12 | |
Cellectar Biosciences | 0.0 | $180k | 53k | 3.40 | |
Cellectar Biosciences Inc *w exp 08/19/201 | 0.0 | $38k | 53k | 0.72 |